MA49368A - Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires - Google Patents

Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires

Info

Publication number
MA49368A
MA49368A MA049368A MA49368A MA49368A MA 49368 A MA49368 A MA 49368A MA 049368 A MA049368 A MA 049368A MA 49368 A MA49368 A MA 49368A MA 49368 A MA49368 A MA 49368A
Authority
MA
Morocco
Prior art keywords
imidazopyrimidines
diazabicyclic
substitute
respiratory tract
tract diseases
Prior art date
Application number
MA049368A
Other languages
English (en)
Other versions
MA49368B1 (fr
Inventor
Udo Albus
Moritz Beck-Broichsitter
Karl Collins
Martina Delbeck
Doris Gehring
Michael Hahn
Niels Lindner
Klemens Lustig
Thomas Müller
Janine Nicolai
Björn Rosenstein
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of MA49368A publication Critical patent/MA49368A/fr
Publication of MA49368B1 publication Critical patent/MA49368B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA49368A 2017-06-14 2018-06-07 Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires MA49368B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17176046 2017-06-14
EP17193252 2017-09-26
EP18728646.3A EP3638675B1 (fr) 2017-06-14 2018-06-07 Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires
PCT/EP2018/064977 WO2018228907A1 (fr) 2017-06-14 2018-06-07 Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires

Publications (2)

Publication Number Publication Date
MA49368A true MA49368A (fr) 2021-04-14
MA49368B1 MA49368B1 (fr) 2024-06-28

Family

ID=62492660

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49368A MA49368B1 (fr) 2017-06-14 2018-06-07 Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires

Country Status (36)

Country Link
US (3) US11098063B2 (fr)
EP (1) EP3638675B1 (fr)
JP (2) JP6896113B2 (fr)
KR (1) KR102364134B1 (fr)
CN (4) CN115583959B (fr)
AR (1) AR112099A1 (fr)
AU (1) AU2018283331B2 (fr)
BR (1) BR112019026450A2 (fr)
CA (1) CA3066942A1 (fr)
CL (1) CL2019003650A1 (fr)
CO (1) CO2019014047A2 (fr)
CR (1) CR20190563A (fr)
CU (1) CU24603B1 (fr)
DO (1) DOP2019000308A (fr)
EA (1) EA202090043A1 (fr)
EC (1) ECSP19088492A (fr)
ES (1) ES2985167T3 (fr)
GE (2) GEAP202115256A (fr)
HR (1) HRP20240678T1 (fr)
HU (1) HUE066512T2 (fr)
IL (1) IL271117B (fr)
JO (1) JOP20190284A1 (fr)
MA (1) MA49368B1 (fr)
MX (2) MX2019014983A (fr)
MY (1) MY204293A (fr)
NI (1) NI201900126A (fr)
NZ (1) NZ758821A (fr)
PE (1) PE20200016A1 (fr)
PH (1) PH12019502828A1 (fr)
PL (1) PL3638675T3 (fr)
RS (1) RS65543B1 (fr)
SG (1) SG11201911508XA (fr)
TW (1) TWI801388B (fr)
UA (1) UA125186C2 (fr)
UY (1) UY37773A (fr)
WO (1) WO2018228907A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018536693A (ja) 2015-12-10 2018-12-13 バイエル・ファルマ・アクティエンゲゼルシャフト 睡眠関連呼吸障害を治療するためのＴＡＳＫ−１およびＴＡＳＫ−２チャネルの遮断薬としての２−フェニル−３−（ピペラジノメチル）イミダゾ［１，２−ａ］ピリジン誘導体
JOP20190284A1 (ar) * 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2018227427A1 (fr) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Dérivés de diazépane pontés substitués et leur utilisation
CA3139298A1 (fr) 2019-05-09 2020-11-12 Bayer Aktiengesellschaft Combinaison d'un antagoniste de recepteur a2-adrenergiques de sous-type c (alpha-2c) avec un bloqueur de canal task-1/3 pour le traitement de l'apnee du sommeil
TW202108139A (zh) * 2019-05-09 2021-03-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之α２—腎上腺素受體亞型Ｃ（α—２Ｃ）拮抗劑與ＴＡＳＫ１／３通道阻斷劑之組合
PE20221025A1 (es) 2019-11-06 2022-06-16 Bayer Ag Inhibidores de los receptores a2c adrenergicos
WO2022008426A1 (fr) * 2020-07-06 2022-01-13 Bayer Aktiengesellschaft COMBINAISON D'ANTAGONISTES D'UN SOUS-TYPE C DE RÉCEPTEUR α2-ADRÉNERGIQUE (ALPHA-2C) AVEC UN BLOQUEUR DE CANAL TASK1/3 POUR LE TRAITEMENT DE L'APNÉE DU SOMMEIL
GB202101734D0 (en) * 2021-02-08 2021-03-24 Cerevance Inc Novel Compounds
CN118434415A (zh) 2021-12-22 2024-08-02 拜耳公司 用于治疗睡眠呼吸暂停的task1/3通道阻断剂与毒蕈碱型受体拮抗剂的结合物
US20250057845A1 (en) 2021-12-22 2025-02-20 Bayer Aktiengesellschaft Combination of a task1/3 channel blocker with a p2x3 receptor antagonist for the treatment of sleep apnea
JP2024545289A (ja) 2021-12-22 2024-12-05 バイエル・アクチエンゲゼルシヤフト 睡眠時無呼吸の治療のためのｔａｓｋ１／３チャネル遮断薬とノルエピネフリン再取込み阻害薬との組合せ
EP4460307A1 (fr) 2022-01-07 2024-11-13 Bayer Aktiengesellschaft Dérivés de 2,3-dihydrobenzo[b][1, 4]dioxin-2-ylméthyl)pipérazin-1-yle pour le traitement de l'apnée du sommeil
EP4460298A1 (fr) 2022-01-07 2024-11-13 Bayer Aktiengesellschaft Antagonistes de sous-type c de ?2-adrénocepteur pour le traitement de l'apnée du sommeil
WO2025068514A1 (fr) 2023-09-28 2025-04-03 Bayer Aktiengesellschaft Carboxamides hétérocycliques substitués et leur utilisation
CN117959293B (zh) * 2024-01-18 2025-05-13 香港大学深圳医院 非奈利酮在制备治疗和/或预防卵巢功能障碍疾病药物中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
WO2002002557A2 (fr) 2000-06-30 2002-01-10 Neurogen Corporation Derives imidazo[1,2-a]pyridine 2-substitues
GB0017256D0 (en) 2000-07-13 2000-08-30 Merck Sharp & Dohme Therapeutic agents
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10247269A1 (de) 2002-10-10 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine
US7855194B2 (en) * 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
BRPI0710946A2 (pt) 2006-04-27 2012-03-06 Sanofi-Aventis Deutschland Gmbh inibidores dos canais de Íon task-1 e task-3
EP2049110B1 (fr) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Diazépans pontés antagonistes du récepteur de l'oréxine
EP1974729A1 (fr) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Dérivés d'imidazopyridine substitués en tant qu'antagonistes du récepteur de la mélanocortine- 4
CA2724842A1 (fr) 2008-05-19 2009-11-26 Sunovion Pharmaceuticals Inc. Composes imidazo[1,2-a]pyridines
WO2011115804A1 (fr) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Stimulateurs de sgc
CA2793086C (fr) 2010-03-18 2018-08-21 Institut Pasteur Korea Composes d'imidazo[1,2-a]pyridine substitue et leur utilisation pour le traitement d'infections bacteriennes
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
TW201242965A (en) 2011-02-01 2012-11-01 Kyowa Hakko Kirin Co Ltd Ring-fused heterocyclic derivative
EP2691392A1 (fr) 2011-03-31 2014-02-05 EMBLEM Technology Transfer GmbH Composés d'imidazo[1,2-a]pyridine pour l'utilisation en thérapie
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
MX2014002968A (es) 2011-09-12 2014-07-09 Sanofi Sa 4,5,6,7 - tetrahidro - 1h - pirazolo [4,3 -c] piridinas sustituidas con indanilo, su uso como medicamento, y preparaciones farmaceuticas que las comprenden.
AU2011376721B2 (en) 2011-09-16 2017-06-08 Sanofi Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
BR112014006180A2 (pt) * 2011-09-16 2017-04-11 Sanofi Sa 4, 5, 6, 7-tetraidro-1h-pirazol [4, 3-c] piridinas substituídas, seu uso como medicamento e preparações farmacêuticas que compreendem as mesmas
JP6126135B2 (ja) 2012-02-03 2017-05-10 サノフイ 縮合ピロールカルボキサミド及びその医薬としてのその使用
SG11201509650YA (en) * 2013-05-24 2015-12-30 Iomet Pharma Ltd Slc2a transporter inhibitors
CA2937616A1 (fr) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Composes bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
TWI585785B (zh) * 2014-11-26 2017-06-01 Murata Manufacturing Co Electronic parts manufacturing methods, electronic components and electronic devices
JP2018012645A (ja) 2014-11-26 2018-01-25 持田製薬株式会社 新規ジアザビシクロ誘導体
US9994570B2 (en) * 2014-11-26 2018-06-12 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists
US10000499B2 (en) 2014-11-26 2018-06-19 Merck Sharp & Dohme Corp. Methyl diazepane orexin receptor antagonists
JP2018016544A (ja) 2014-12-03 2018-02-01 持田製薬株式会社 新規ジアザビシクロ［２．２．２］オクタン誘導体
WO2017050732A1 (fr) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
WO2017097671A1 (fr) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft Dérivés de perhydropyrrolo[3,4-c]pyrrole substitués et leur utilisation
JP2018536693A (ja) 2015-12-10 2018-12-13 バイエル・ファルマ・アクティエンゲゼルシャフト 睡眠関連呼吸障害を治療するためのＴＡＳＫ−１およびＴＡＳＫ−２チャネルの遮断薬としての２−フェニル−３−（ピペラジノメチル）イミダゾ［１，２−ａ］ピリジン誘導体
JOP20190005A1 (ar) 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
JOP20190141A1 (ar) 2016-12-21 2019-06-12 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
JOP20190148A1 (ar) 2016-12-21 2019-06-18 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2018227427A1 (fr) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Dérivés de diazépane pontés substitués et leur utilisation
PE20211285A1 (es) 2018-11-27 2021-07-19 Bayer Ag Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios
TW202108139A (zh) 2019-05-09 2021-03-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之α２—腎上腺素受體亞型Ｃ（α—２Ｃ）拮抗劑與ＴＡＳＫ１／３通道阻斷劑之組合
CA3139298A1 (fr) 2019-05-09 2020-11-12 Bayer Aktiengesellschaft Combinaison d'un antagoniste de recepteur a2-adrenergiques de sous-type c (alpha-2c) avec un bloqueur de canal task-1/3 pour le traitement de l'apnee du sommeil

Also Published As

Publication number Publication date
NI201900126A (es) 2020-04-02
PH12019502828A1 (en) 2020-10-26
CU20190101A7 (es) 2020-10-20
CU24603B1 (es) 2022-06-06
JP2020523388A (ja) 2020-08-06
UY37773A (es) 2019-01-02
AU2018283331B2 (en) 2022-08-04
DOP2019000308A (es) 2020-01-31
KR102364134B1 (ko) 2022-02-18
JP2021127346A (ja) 2021-09-02
HUE066512T2 (hu) 2024-08-28
TWI801388B (zh) 2023-05-11
US11098063B2 (en) 2021-08-24
KR20200014915A (ko) 2020-02-11
MX2022012716A (es) 2022-11-07
CL2019003650A1 (es) 2020-07-10
PE20200016A1 (es) 2020-01-06
CN115554300B (zh) 2024-10-29
GEAP202115256A (en) 2021-10-11
US20220017540A1 (en) 2022-01-20
SG11201911508XA (en) 2020-01-30
HRP20240678T1 (hr) 2024-08-16
TW201919638A (zh) 2019-06-01
BR112019026450A2 (pt) 2020-07-14
EP3638675B1 (fr) 2024-04-17
IL271117B (en) 2022-03-01
CN115583959A (zh) 2023-01-10
EP3638675A1 (fr) 2020-04-22
JP6896113B2 (ja) 2021-06-30
PL3638675T3 (pl) 2024-07-01
CN110719911B (zh) 2022-10-21
RS65543B1 (sr) 2024-06-28
AR112099A1 (es) 2019-09-18
CA3066942A1 (fr) 2018-12-20
US20200109155A1 (en) 2020-04-09
MA49368B1 (fr) 2024-06-28
CN115554300A (zh) 2023-01-03
EP3638675C0 (fr) 2024-04-17
US20250154175A1 (en) 2025-05-15
CN115583959B (zh) 2024-04-26
MY204293A (en) 2024-08-21
MX2019014983A (es) 2020-02-24
JOP20190284A1 (ar) 2019-12-11
ES2985167T3 (es) 2024-11-04
IL271117A (en) 2020-01-30
UA125186C2 (uk) 2022-01-26
NZ758821A (en) 2025-05-02
CN115554299A (zh) 2023-01-03
CO2019014047A2 (es) 2020-01-17
EA202090043A1 (ru) 2020-04-02
GEP20227366B (en) 2022-03-25
US12180227B2 (en) 2024-12-31
CN110719911A (zh) 2020-01-21
CR20190563A (es) 2020-04-22
WO2018228907A1 (fr) 2018-12-20
ECSP19088492A (es) 2019-12-27
AU2018283331A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
MA49368A (fr) Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires
FR22C1011I1 (fr) Promedicaments de fumarates et leur utilisation pour le traitement de diverses maladies
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3337465A4 (fr) Compositions et méthodes d'utilisation en association destinées au traitement et au diagnostic de maladies auto-immunes
EP3709882A4 (fr) Attelles diagnostiques et thérapeutiques
LT3240554T (lt) Blautia stercosis ir wexlerae, skirtos naudoti uždegiminių ir autoimuninių ligų gydymui
EP3363507C0 (fr) Système de gestion pour jeux de table et monnaie de substitution pour jeu
SI3377637T1 (sl) Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
EP3273955A4 (fr) Traitement de maladies respiratoires
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
CY1126258T1 (el) Ενωσεις ινδολινονης και χρηση αυτων στη θεραπεια ινωτικων ασθενειων
MA44126A (fr) Méthodes de traitement de maladies et troubles pulmonaires
EP2969010A4 (fr) Utilisation de levocetirizine et de montelukast dans le traitement des maladies auto-immunes
HUE037663T2 (hu) Kalcitonin mimetikumok betegségek és rendellenességek kezelésére
IL283469A (en) Inhalable preparations for use in the treatment of lung diseases
EP3481958A4 (fr) Procédés et compositions de traitement de troubles et de maladies impliquant rdh12
EP3344258A4 (fr) Traitement de maladies auto-immunes et de maladies auto-inflammatoires
EP3729452C0 (fr) Système et procédé d'entraînement d'inhalateur
EP3395341A4 (fr) Composition pour le traitement de maladies neuromotrices et son utilisation
EP3423461A4 (fr) Composés de sélénogalactoside pour la prévention et le traitement de maladies associées à la galectine et leur utilisation
EP2945953A4 (fr) Composés tétracycliques à substitution thiophène et leurs méhodes d'utilisation pour le traitement de maladies virales
EP3353159A4 (fr) Cytotoxines modifiées et leur utilisation thérapeutiques
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
EP3341012A4 (fr) Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
HUE065202T2 (hu) Készítmény bélelváltozások kezelésében való felhasználásra